Gain Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

GANX$1.08-0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS


· Three Months Ended September 30 · Nine Months Ended September 30
· 2025 · 2024 · 2025 · 2024
Operating expenses: · · · ·
Research and development	$(2,849,510)	$(2,621,722)	$(7,865,493)	$(9,566,259)
General and administrative	(1,936,267)	(1,837,242)	(6,379,186)	(7,453,229)
Total operating expenses	(4,785,777)	(4,458,964)	(14,244,679)	(17,019,488)

Loss from operations	(4,785,777)	(4,458,964)	(14,244,679)	(17,019,488)

Other income (expense):
Interest income, net	78,074	105,405	161,055	305,239
Foreign exchange (loss) gain, net	(27,382)	(121,139)	(748,892)	103,362
Loss before income tax	(4,735,085)	(4,474,698)	(14,832,516)	(16,610,887)

Income tax	(549,288)	(10,994)	(791,002)	(32,077)

Net loss	$(5,284,373)	$(4,485,692)	$(15,623,518)	$(16,642,964)

Net loss per share:
Net loss per share attributable to common stockholders - basic and diluted	$(0.15)	$(0.17)	$(0.50)	$(0.78)
Weighted average common stock - basic and diluted	34,998,060	26,531,747	31,351,432	21,273,422

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.